| Literature DB >> 33148343 |
Elizabeth McInnes1, Simeon Dale2, Louise Craig2, Rosemary Phillips2, Oyebola Fasugba3, Verena Schadewaldt4,5, N Wah Cheung6, Dominique A Cadilhac7,8, Jeremy M Grimshaw9,10, Chris Levi11, Julie Considine12,13, Patrick McElduff14, Richard Gerraty15,16, Mark Fitzgerald17,18, Jeanette Ward19, Catherine D'Este20,21, Sandy Middleton2.
Abstract
BACKGROUND: The implementation of evidence-based protocols for stroke management in the emergency department (ED) for the appropriate triage, administration of tissue plasminogen activator to eligible patients, management of fever, hyperglycaemia and swallowing, and prompt transfer to a stroke unit were evaluated in an Australian cluster-randomised trial (T3 trial) conducted at 26 emergency departments. There was no reduction in 90-day death or dependency nor improved processes of ED care. We conducted an a priori planned process influential factors that impacted upon protocol uptake.Entities:
Keywords: Acute stroke; Emergency departments; Normalisation process theory; Process evaluation; Qualitative design
Mesh:
Substances:
Year: 2020 PMID: 33148343 PMCID: PMC7640433 DOI: 10.1186/s13012-020-01057-0
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
T3 Trial intervention components
| | |
| • All patients presenting with signs and symptoms of suspected stroke should be triaged to Australasia Triage Scale (ATS) categories 1 or 2 (seen within 10 min) | |
| | |
| Thrombolysis (tissue-type plasminogen activator) | |
| • All patients to be assessed for thrombolysis eligibility | |
| • All eligible patients to receive thrombolysis | |
| Fever | |
| • All patients to have their temperature taken on admission to emergency department (ED) and then at least four hourly whilst they remain in ED | |
| • Treat temperature 37.5 °C or greater with paracetamol within 1 h | |
| Sugar | |
| • Formal venous (laboratory) blood glucose level (BGL) on admission to ED | |
| • Record finger prick BGL on ED admission and monitor finger prick BGL every 6 h (or greater if elevated) | |
| • Administer insulin to all patients with BGL > 10 mmol/L (180 mg/dL) within 1 h | |
| Swallow | |
| • Patients remain Nil By Mouth until a swallow screen by non-speech pathologist (SP) or swallow assessment by SP performed, i.e.: | |
| ◦ No oral food or fluids to be given prior to swallow screen by non-SP or swallow assessment by SP | |
| ◦ No oral medications administered prior to swallow screen by non-SP or swallow assessment by SP | |
| • All patients who fail the screen are to be assessed by a SP | |
| | |
| • All patients with stroke to be discharged from ED within 4 h | |
| • All patients with stroke to be admitted to the hospital’s stroke unit | |
| | |
| | |
| • To present the details of the trial | |
| • To identify the local barriers and enablers | |
| • To identify the local site clinical champion | |
| | |
| • To discuss the action plan to address the barriers | |
| • To ascertain the actions already taken to address the barriers | |
| • To identify the new local barriers | |
| | |
| • A 20-min PowerPoint presentation and a 10-min discussion | |
| • An 8-min video developed by an academic ED nurse clinician/opinion leader | |
| | |
| • Key national clinical opinion leaders at Workshop 1 and available as needed for any site-requested queries | |
| • Clinical champions from ED and stroke unit | |
| • | |
| • Reminder poster to display in ED- and pocket-sized card to attach to ID lanyard for staff | |
| • Proactive direct contact every 6 weeks in the form of the following: | |
| ◦ Site visits every 3 months (face-to-face) using an action plan | |
| ◦ Teleconferences every 3 months with clinical champions and site coordinator using an action plan | |
| • Emails—reactive and monthly proactive emails | |
| • Telephone support—reactive | |
| • Telephone support—reactive and as needed |
“On admission” defined as within 60 min of arrival to ED. Four hourly defined as within 4.5 h. Six hourly defined as within 6.5 h
aFace-to-face multidisciplinary group sessions held at each intervention site
Fig. 1Overview of T3 Trial with process evaluation
Description of participants by group
| Participant group | Description |
|---|---|
| ED medical director | Partner researcher and senior medical officer responsible for delivery of ED medical services and for supporting implementation |
| ED nurse unit manager | Emergency department nurse manager with detailed knowledge of ED clinical operation. |
| ED clinical champion | Senior emergency nurse clinician/educator from participating hospital’s ED appointed as clinical champion to support intervention implementation and liaise with the Trial State Co-ordinator |
| Stroke unit clinical champion | Senior nurse clinician or educator from participating hospital’s stroke unit appointed as clinical champion to support intervention implementation and liaise with ED clinical champion |
| ED nurse | Nurses involved in delivery of emergency care |
| Trial state co-ordinator | Nurse/psychology graduate employed to provide support to intervention sites to address barriers (one co-ordinator each for New South Wales/Australian Capital Territory, Victoria and Queensland) |
Demographic and professional characteristics of participants (n = 28)
| Participant group | Median number of years in ED or stroke care (range) | Sex ratio female/male |
|---|---|---|
| ED medical director ( | 18.5 (15–20) | All males |
| ED nurse unit manager ( | 18.0 (16–20) | All females |
| ED clinical champion ( | 13.5 (8–20) | 3:1 |
| Stroke unit clinical champion ( | 9.0 (4–13) | 3:1 |
| ED nurse ( | 6.8 (2.5–12) | All females |
| Trial state co-ordinator ( | N/A | All females |
Themes and sub-themes
| Themes and sub-themes | Normalisation process theory concept |
|---|---|
Mobilising teams Authority to implement | |
Engaging with the evidence Adherence versus adaptation | |
Defining professional boundaries Care trajectory |